Latest Insider Transactions at Phreesia, Inc. (PHR)
This section provides a real-time view of insider transactions for Phreesia, Inc. (PHR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Phreesia, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Phreesia, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jan 23
2025
|
Balaji Gandhi Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,900
+5.01%
|
-
|
Jan 23
2025
|
Allison C Hoffman General Counsel & Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
12,791
+7.45%
|
-
|
Jan 23
2025
|
Evan Roberts Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,564
+2.46%
|
-
|
Jan 23
2025
|
David Linetsky SVP, Life Sciences |
BUY
Grant, award, or other acquisition
|
Direct |
19,564
+7.45%
|
-
|
Jan 23
2025
|
Chaim Indig Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
48,910
+3.66%
|
-
|
Jan 23
2025
|
Amy Beth Van Duyn SVP, Human Resources |
BUY
Grant, award, or other acquisition
|
Direct |
7,900
+6.26%
|
-
|
Jan 21
2025
|
Balaji Gandhi Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,827
-3.95%
|
$157,329
$27.31 P/Share
|
Jan 21
2025
|
Allison C Hoffman General Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
8,426
-5.45%
|
$227,502
$27.31 P/Share
|
Jan 21
2025
|
Evan Roberts Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
12,749
-1.66%
|
$344,223
$27.31 P/Share
|
Jan 21
2025
|
Amy Beth Van Duyn SVP, Human Resources |
SELL
Open market or private sale
|
Direct |
4,720
-4.1%
|
$127,440
$27.31 P/Share
|
Jan 21
2025
|
Chaim Indig Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
21,692
-1.72%
|
$585,684
$27.31 P/Share
|
Jan 21
2025
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Direct |
13,873
-5.85%
|
$374,571
$27.31 P/Share
|
Jan 15
2025
|
Allison C Hoffman General Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
4,585
-1.45%
|
$119,210
$26.93 P/Share
|
Jan 15
2025
|
Yvonne Hui Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
381
-1.46%
|
$9,906
$26.87 P/Share
|
Jan 15
2025
|
Amy Beth Van Duyn SVP, Human Resources |
SELL
Open market or private sale
|
Direct |
604
-0.52%
|
$15,704
$26.98 P/Share
|
Jan 15
2025
|
Chaim Indig Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,990
-0.24%
|
$77,740
$26.98 P/Share
|
Jan 15
2025
|
Balaji Gandhi Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
836
-0.56%
|
$21,736
$26.98 P/Share
|
Jan 15
2025
|
Evan Roberts Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,785
-0.23%
|
$46,410
$26.98 P/Share
|
Jan 15
2025
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Direct |
1,946
-0.81%
|
$50,596
$26.98 P/Share
|
Jan 14
2025
|
Yvonne Hui Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
362
-1.37%
|
$9,412
$26.38 P/Share
|
Jan 10
2025
|
Yvonne Hui Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
388
-1.44%
|
$10,476
$27.85 P/Share
|
Jan 08
2025
|
Evan Roberts Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,681
-0.17%
|
$75,068
$28.07 P/Share
|
Jan 08
2025
|
Yvonne Hui Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
288
-1.06%
|
$8,064
$28.0 P/Share
|
Jan 07
2025
|
Evan Roberts Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
7,319
-0.94%
|
$197,613
$27.0 P/Share
|
Jan 06
2025
|
Amy Beth Van Duyn SVP, Human Resources |
SELL
Open market or private sale
|
Direct |
1,311
-1.12%
|
$34,086
$26.61 P/Share
|
Jan 06
2025
|
Balaji Gandhi Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,195
-2.11%
|
$83,070
$26.61 P/Share
|
Jan 06
2025
|
Evan Roberts Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,873
-0.37%
|
$74,698
$26.61 P/Share
|
Jan 06
2025
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Direct |
3,133
-1.29%
|
$81,458
$26.61 P/Share
|
Jan 06
2025
|
Allison C Hoffman General Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
3,982
-2.44%
|
$103,532
$26.61 P/Share
|
Jan 06
2025
|
Chaim Indig Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,375
-0.42%
|
$139,750
$26.61 P/Share
|
Jan 02
2025
|
Chaim Indig Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
46,948
+3.57%
|
-
|
Jan 02
2025
|
Evan Roberts Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
53,990
+6.45%
|
-
|
Jan 02
2025
|
Allison C Hoffman General Counsel & Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
46,525
+22.19%
|
-
|
Jan 02
2025
|
David Linetsky SVP, Life Sciences |
BUY
Grant, award, or other acquisition
|
Direct |
53,990
+18.22%
|
-
|
Jan 02
2025
|
Balaji Gandhi Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
53,990
+26.25%
|
-
|
Jan 02
2025
|
Amy Beth Van Duyn SVP, Human Resources |
BUY
Grant, award, or other acquisition
|
Direct |
23,474
+16.72%
|
-
|
Dec 31
2024
|
Allison C Hoffman General Counsel & Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
298
+0.25%
|
$5,066
$17.57 P/Share
|
Dec 31
2024
|
Yvonne Hui Principal Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
388
+1.41%
|
$6,596
$17.57 P/Share
|
Dec 18
2024
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Indirect |
24
-0.27%
|
$600
$25.38 P/Share
|
Dec 18
2024
|
Allison C Hoffman General Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
3,495
-2.92%
|
$83,880
$24.88 P/Share
|
Dec 17
2024
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Indirect |
61
-0.34%
|
$1,525
$25.41 P/Share
|
Dec 16
2024
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Indirect |
35
-0.39%
|
$840
$24.88 P/Share
|
Dec 16
2024
|
Michael Weintraub Director |
SELL
Open market or private sale
|
Direct |
861
-0.35%
|
$21,525
$25.26 P/Share
|
Dec 16
2024
|
Michael Weintraub Director |
BUY
Exercise of conversion of derivative security
|
Direct |
861
+0.35%
|
$3,444
$4.71 P/Share
|
Dec 13
2024
|
Michael Weintraub Director |
SELL
Open market or private sale
|
Direct |
20,565
-7.81%
|
$514,125
$25.04 P/Share
|
Dec 13
2024
|
Michael Weintraub Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,565
+7.24%
|
$82,260
$4.71 P/Share
|
Dec 11
2024
|
Michael Weintraub Director |
SELL
Open market or private sale
|
Direct |
18,574
-7.11%
|
$464,350
$25.1 P/Share
|
Dec 11
2024
|
Michael Weintraub Director |
BUY
Exercise of conversion of derivative security
|
Direct |
18,574
+6.63%
|
$74,296
$4.71 P/Share
|
Dec 11
2024
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Direct |
11,853
-5.92%
|
$284,472
$24.85 P/Share
|
Dec 10
2024
|
Evan Roberts Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
25,000
-3.32%
|
$600,000
$24.09 P/Share
|